2023 World Conference on Lung Cancer (Posters)-EP12.01. Lazertinib in Pretreated Epidermal Growth Factor Receptor T790M-Mutated Advanced Non-small Cell Lung Cancer: A Real-World Multicenter Study

EP12.01. Lazertinib in Pretreated Epidermal Growth Factor Receptor T790M-Mutated Advanced Non-small Cell Lung Cancer: A Real-World Multicenter Study - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to collect real-world data on the efficacy and safety of lazertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. The study included patients with T790M-mutated non-small cell lung cancer who had previously been treated with an EGFR-TKI. The primary outcome measure was progression-free survival (PFS), and secondary outcomes included overall survival, duration of response, objective response rate, and disease control rate. <br /><br />The study involved 103 patients, with 90 receiving lazertinib as a second- or third-line therapy. The objective response rate (ORR) was 62.1%, and the disease control rate (DCR) was 94.2%. The median follow-up duration was 11.1 months, and the median PFS period was 13.9 months. The study also evaluated a subgroup of 33 patients with brain metastases, finding a 93.5% intracranial disease control rate and 57.6% objective response rate. The median intracranial PFS period was 17.1 months. <br /><br />Adverse events led to dose modification or discontinuation in 17.5% of patients, with the most common being grade 1 or 2 paresthesia. <br /><br />Overall, the study found that lazertinib demonstrated efficacy and safety in a real-world setting, providing durable disease control both systemically and intracranially. The side effects were manageable. <br /><br />In summary, the real-world multicenter study evaluated the efficacy and safety of lazertinib in pretreated non-small cell lung cancer patients with the T790M EGFR mutation. The study showed promising results, with a high disease control rate and manageable side effects.

Asset Subtitle

Beung-chul Ahn

Meta Tag

Speaker Beung-chul Ahn

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

lazertinib

epidermal growth factor receptor

EGFR

tyrosine kinase inhibitor

non-small cell lung cancer

T790M mutation

progression-free survival

overall survival

objective response rate

disease control rate